BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Glutamic-pyruvic transaminase 2 (GPT2); activating transcription factor 4 (ATF4); phosphoinositide 3-kinase catalytic subunit α polypeptide (PI3KC

...Cancer INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting GPT2 or ATF4...
...or ATF4 could help treat PI3KCA-mutant colorectal cancer. In tumor samples from colorectal cancer patients, GPT2...
...cell lines, a GPT2 inhibitor tool compound or siRNA targeting ATF4 - which positively regulates GPT2...
BioCentury | Feb 27, 2006
Clinical News

Tasmar regulatory update

FDA approved less restrictive labeling for Tasmar to treat Parkinson's disease (PD) in patients undergoing treatment with levodopa/cardiodopa. The new labeling calls for less frequent laboratory monitoring for patients taking Tasmar, and allows patients to...
BioCentury | Dec 20, 1999
Company News

Cholestech sales and marketing update

CTEC launched its alanine aminotransferase (ALT) test for liver function, also known as its serum glutamic-pyruvic transaminase (SGPT) test. The test, which is used with CTEC's LoDoX system and sells for $4.50 per cassette, has...
Items per page:
1 - 3 of 3